Clinical Trials Directory

Trials / Completed

CompletedNCT03740776

The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI

The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in Patients With ST-elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention

Status
Completed
Phase
Study type
Observational
Enrollment
2 (actual)
Sponsor
Dongying Zhang · Academic / Other
Sex
All
Age
20 Years – 85 Years
Healthy volunteers

Summary

Eosinophils (EOS) in peripheral blood are significantly decreased in ST-segment elevation myocardial infarction (STEMI) and the reduced EOS indicates severe myocardial damage. Whether EOS is a good predictor for in-hospital major adverse cardiac events (MACEs) of patients with ST-segment elevation myocardial infarction remains unknown. The aims of this study was to evaluate prognostic role of EOS for in-hospital MACEs in STEMI patients who have undergone primary percutaneous coronary intervention (PCI)

Detailed description

The investigators retrospectively analyzed the clinical data of 518 patients with STEMI after PCI. MACEs were defined as cardiac arrest, cardiac rapture, malignant arrhythmia and cardiac death. The receiver operating characteristic (ROC) curves were used to demonstrate the prognostic value of EOS% in in-hospital MACEs. All patients were divided into 2 groups according to the best cut-off EOS% value, including reduced EOS% group and control group. Cox regression analyses and KM survival curve were used to calculate the correlated between EOS with in-hospital MACEs.

Conditions

Timeline

Start date
2015-10-01
Primary completion
2017-08-01
Completion
2018-11-01
First posted
2018-11-14
Last updated
2018-11-14

Source: ClinicalTrials.gov record NCT03740776. Inclusion in this directory is not an endorsement.